Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Radius Health reports phase III topline results for abaloparatide-SC

Dec. 24, 2014

Fate Therapeutics reports interim data from phase II trial of Prohema

Dec. 23, 2014

CHMP backs approval of Orexigen's naltrexone/bupropion for weight management

Dec. 22, 2014

SOV Therapeutics' oral testosterone undecanoate meets phase IIb study endpoints

Dec. 22, 2014

Amunix confirms option exercise by Eli Lilly for XTEN product

Dec. 19, 2014

Bone Therapeutics' phase I/IIa trial of Allob in delayed-union fractures recommended to continue

Dec. 19, 2014

Ascendis reports interim data from phase II pediatric study of TransCon Growth Hormone

Dec. 19, 2014

Poxel reports results from phase IIb trial of imeglimin in type 2 diabetes

Dec. 18, 2014

Capstone Therapeutics reports phase Ib/IIa study results for AEM-28

Dec. 18, 2014

Sichuan Haisco Pharmaceutical synthesizes novel FFAR1 agonists for diabetes

Dec. 18, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 7, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...